1. Home
  2. SCYX vs OCC Comparison

SCYX vs OCC Comparison

Compare SCYX & OCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • OCC
  • Stock Information
  • Founded
  • SCYX 1999
  • OCC 1983
  • Country
  • SCYX United States
  • OCC United States
  • Employees
  • SCYX N/A
  • OCC N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • OCC Telecommunications Equipment
  • Sector
  • SCYX Health Care
  • OCC Industrials
  • Exchange
  • SCYX Nasdaq
  • OCC Nasdaq
  • Market Cap
  • SCYX 28.5M
  • OCC 23.4M
  • IPO Year
  • SCYX 2014
  • OCC 1996
  • Fundamental
  • Price
  • SCYX $0.82
  • OCC $6.03
  • Analyst Decision
  • SCYX
  • OCC
  • Analyst Count
  • SCYX 0
  • OCC 0
  • Target Price
  • SCYX N/A
  • OCC N/A
  • AVG Volume (30 Days)
  • SCYX 176.2K
  • OCC 716.2K
  • Earning Date
  • SCYX 08-07-2025
  • OCC 09-10-2025
  • Dividend Yield
  • SCYX N/A
  • OCC N/A
  • EPS Growth
  • SCYX N/A
  • OCC N/A
  • EPS
  • SCYX N/A
  • OCC N/A
  • Revenue
  • SCYX $2,630,000.00
  • OCC $68,999,601.00
  • Revenue This Year
  • SCYX $463.61
  • OCC N/A
  • Revenue Next Year
  • SCYX $310.80
  • OCC N/A
  • P/E Ratio
  • SCYX N/A
  • OCC N/A
  • Revenue Growth
  • SCYX N/A
  • OCC 5.77
  • 52 Week Low
  • SCYX $0.66
  • OCC $2.02
  • 52 Week High
  • SCYX $2.29
  • OCC $7.00
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 57.87
  • OCC 84.68
  • Support Level
  • SCYX $0.67
  • OCC $4.60
  • Resistance Level
  • SCYX $0.75
  • OCC $5.70
  • Average True Range (ATR)
  • SCYX 0.04
  • OCC 0.55
  • MACD
  • SCYX 0.01
  • OCC 0.30
  • Stochastic Oscillator
  • SCYX 93.53
  • OCC 78.49

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About OCC Optical Cable Corporation

Optical Cable Corp manufactures tight-buffered fiber optic & copper data communication cables, data communication connectivity solutions for enterprise markets, and customized solutions for specialty use & harsh environments. Its products and services include designs and customized products for specialty applications and harsh environments, cabling, connectors, patch cords, assemblies, racks, cabinets, datacom enclosures, patch panels, faceplates, and multi-media boxes. The company supplies its products and services to industries such as the military, industrial, mining, petrochemical, renewable energy and broadcast applications, and for the wireless carrier market.

Share on Social Networks: